Who is the CEO of Nephrocare Health Services Ltd?
- Answer Field
-
Vikram Vuppala is the Founder Chairman and the Managing Director of the company.
Nephrocare Health Services Ltd. operates a network of dialysis clinics offering diagnosis, haemodialysis, home and mobile dialysis, and related wellness programmes supported by an internal pharmacy model. The organisation functions across multiple regions in India and selected international locations through clinic-based operations and partnerships with hospitals to manage in-house dialysis centres. Its presence across several cities, including tier II and tier III locations, positions the company within a segment that addresses growing demand for structured dialysis care. The business approach reflects a focus on accessible dialysis treatment supported by a diversified service offering within the kidney care space.
Investors can apply for the IPO online through supported platforms using the ASBA facility available in their bank account. The application can be submitted by logging into the net banking portal, selecting the IPO section, choosing the relevant offering, and placing a bid within the available price range. Another option is to apply through authorised broking platforms by completing the application form and using the UPI process, subject to the application window and eligibility conditions as published in official exchange communication. Applicants may refer to the company’s prospectus and exchange filings before making any investment decision.
For more details, visit the Nephrocare Health Services Limited IPO page.
Details | Information |
IPO Date | December 10, 2025 to December 12, 2025 |
Issue Size | 1,89,35,819 shares (aggregating up to ₹871.05 Cr) |
Price Band | ₹438 to ₹460 per share |
Lot Size | 32 shares |
Listing At | BSE, NSE |
Capital expenditure by the Company for opening new dialysis clinics in India
Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the Company
General corporate purposes
Event | Date |
|---|---|
IPO Open Date | Wed, Dec 10, 2025 |
IPO Close Date | Fri, Dec 12, 2025 |
Tentative Allotment | Mon, Dec 15, 2025 |
Initiation of Refunds | Tue, Dec 16, 2025 |
Credit of Shares to Demat | Tue, Dec 16, 2025 |
Tentative Listing Date | Wed, Dec 17, 2025 |
Cut-off time for UPI mandate confirmation | 5 PM on Fri, Dec 12, 2025 |
₹438 to ₹460 per share
Application | Lots | Shares | Amount |
Retail (Min) | 1 | 32 | ₹14,720 |
Retail (Max) | 13 | 416 | ₹1,91,360 |
S-HNI (Min) | 14 | 448 | ₹2,06,080 |
S-HNI (Max) | 67 | 2,144 | ₹9,86,240 |
B-HNI (Min) | 68 | 2,176 | ₹10,00,960 |
The Nephrocare Health Services Limited IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Access your trading account using the broker's app or website.
Go to the IPO section to view active IPO listings.
Locate Nephrocare Health Services Limited IPO in the list of available IPOs and click the ‘Apply’ button.
Specify the number of shares (lot size: 32 shares) within the price band of ₹438 to ₹460 per share.
Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Submit the application and monitor the allotment status to check if shares have been allocated to you.
Total Assets: Grew from ₹666.23 crore in FY23 to ₹1,193.68 crore as of Sept 2025.
Total income: Reached ₹483.97 crore in FY25.
Profit After Tax (PAT): Stood at ₹14.23 crore for Sept 2025.
Net Worth: Recorded at ₹716.06 crore in FY25.
Reserves and surplus: Stood at ₹704.14 crore in FY25.
EBITDA: Stood at ₹110.31 crore in Sept 2025.
The company recorded an increase in its total assets over the recent financial periods, reflecting expansion in its operational base and investments.
Total income showed consistent growth during the latest financial year, supported by the scale of its clinic network and service portfolio.
Profit after tax remained positive during the latest reporting period, indicating a stable earnings position.
Net worth increased over time, supported by retained earnings and internal reserves.
Reserves and surplus strengthened during the reporting period, reflecting accumulated profits and a more resilient balance sheet.
Operating performance showed a positive earnings contribution before interest, tax, depreciation, and amortisation in the latest period, indicating continued operational activity across the network.
Overall financial trends suggest an expansion in business scale supported by asset growth, rising income, and steady profitability.
The business operates in a specialised healthcare segment where performance may depend on regulatory requirements, reimbursement policies, and operational compliance across multiple locations.
Expansion into new regions and continuous clinic management may involve costs, capacity planning, and availability of qualified medical personnel, which can influence financial outcomes.
The company has a presence across several cities, including tier II and tier III locations, which indicates access to a wider patient base requiring structured dialysis care.
Partnerships with hospitals for in-house dialysis centres and the availability of diversified dialysis formats, including home and mobile services, may support expansion of its service portfolio.
KPI | Values |
ROE | 13.45% |
ROCE | 18.67% |
RoNW | 13.19% |
PAT Margin | 8.88% |
EBITDA Margin | 22.05% |
Price-to-Book Value | 7.72 |
Registrar | Lead Manager(s) |
|---|---|
Kfin Technologies Ltd. | ICICI Securities Ltd. |
Nephrocare Health Services Ltd.
5th Floor, D Block, iLabs Centre,
Plot 18, Software Units Layout,
Survey No. 64, Madhapur, Shaikpet,
Hyderabad, Telangana, 500081
Phone: +91 40 4240 8039
Email: cs@nephroplus.com
Website: http://www.nephroplus.com/
The Nephrocare Health Services Limited IPO provides information on the company’s dialysis clinic network, its service portfolio, and its presence across several regions in India and selected international locations. The organisation operates through a combination of standalone clinics and partnerships with hospitals for in-house dialysis centres, creating multiple access points for treatment. The offering also includes details related to the issue structure, price band, timeline, and the stated objectives in the prospectus.
Applicants can review the information presented in the draft red herring prospectus and refer to official exchange filings to understand the operational and financial history of the company. The decision to apply may be supported through the ASBA facility in eligible bank accounts or through authorised broking platforms during the subscription period. Investors may consider reviewing disclosures on risks, business structure, and regulatory aspects before completing any application.
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Nephrocare Health Services IPO allotment status.
No result found
Vikram Vuppala is the Founder Chairman and the Managing Director of the company.
The IPO of Nephrocare Health Services is scheduled to open for subscription on 10 December 2025 and will close on 12 December 2025.
Nephrocare Health Services operates a network of dialysis clinics offering in-clinic haemodialysis, home dialysis, mobile dialysis, wellness support, and associated pharmacy services. The business model includes a combination of standalone clinics and partnerships with hospitals for in-house dialysis centres, which allows the company to reach a wide geographic area including tier II and tier III cities in India and a few international markets. The recurring nature of renal care, along with diversified service offerings and an expanded clinic network, supports the structural sustainability of the business model, provided operational and quality standards are maintained.
The total issue size of the IPO is ₹ 871.05 crore.
In the context of this IPO, ‘pre-apply’ generally refers to preparing in advance to submit an application — ensuring that the applicant’s bank account or UPI setup is ready before the subscription opens. The company’s IPO documentation indicates that subscriptions will open on 10 December 2025 and close on 12 December 2025.
The minimum lot size for the IPO is 32 shares.
The allotment date is expected to be 15 December 2025, following the subscription period.
The registrar for the IPO is Kfin Technologies Limited.
Based on the available public disclosures, there is no widely reported governance issue or red flag associated with the company’s leadership or board structure. The available filings and disclosures do not show any alerting items in this regard.
To apply, an investor can log in to a trading platform or banking portal, navigate to the IPO section, and select Nephrocare Health Services IPO. Then choose the number of shares (in lots of 32), provide a UPI ID for payment authorisation, confirm the application before the deadline (5 PM on the closing date), and submit. The funds will be blocked until allotment is finalised.
Yes — a Demat account is required for holding the shares if allotment happens, since the shares will be credited in dematerialized form in your Demat account after listing.
After allotment on 15 December 2025, the registrar (Kfin Technologies Limited) website will host an allotment status portal, where you can enter your PAN or application number to check if shares have been allocated. Once you receive confirmation and shares are credited to your Demat account, you will know the application was successful.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading